Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Preface441
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign390
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future266
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”209
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus188
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?134
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity123
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity104
Approaches to quantifying hepatitis B virus covalently closed circular DNA97
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer95
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"90
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation88
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis81
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 202375
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)71
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials68
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases68
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A66
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”66
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study61
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target59
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease57
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c54
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”54
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis54
Liver organoids: Current advances and future applications for hepatology52
Toward hepatitis C virus elimination using artificial intelligence52
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma50
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease50
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari47
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma47
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma44
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial43
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–202343
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment42
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate41
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe41
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs40
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?40
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review39
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”39
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”39
0.028162956237793